Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.87 and traded as low as $17.27. Pulse Biosciences shares last traded at $17.30, with a volume of 92,403 shares.
Analysts Set New Price Targets
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research report on Friday, September 20th.
Get Our Latest Report on Pulse Biosciences
Pulse Biosciences Stock Down 2.6 %
The stock's 50-day moving average is $17.87 and its 200 day moving average is $13.66. The stock has a market capitalization of $1.06 billion, a PE ratio of -21.36 and a beta of 1.74.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. Creative Planning grew its position in Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company's stock worth $384,000 after acquiring an additional 11,667 shares in the last quarter. Quest Partners LLC bought a new stake in Pulse Biosciences in the second quarter worth approximately $91,000. Rhumbline Advisers grew its position in Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after acquiring an additional 1,608 shares in the last quarter. Bank of New York Mellon Corp grew its position in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after acquiring an additional 9,639 shares in the last quarter. Finally, Westside Investment Management Inc. grew its position in Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock worth $712,000 after acquiring an additional 31,440 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
